Exscientia plc (0RK.SG)
Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
At close: 08:05AM CEST
| Previous close | 4.7600 |
| Open | 4.7400 |
| Bid | 4.8800 x N/A |
| Ask | 4.9800 x N/A |
| Day's range | 4.7400 - 4.7400 |
| 52-week range | 3.6600 - 8.5500 |
| Volume | |
| Avg. volume | 122 |
| Market cap | 626.581M |
| Beta (5Y monthly) | 0.84 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.2300 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireExscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout
OXFORD, England, July 18, 2024--Exscientia plc (Nasdaq: EXAI) today announced it has reached an agreement to acquire GT Apeiron’s share of its oral CDK7 inhibitor programme, gaining full control of GTAEXS617 (‘617) and all related intellectual property.
ZacksAmazon (AMZN) Expands AWS Clientele With Exscientia Deal
Amazon's (AMZN) AWS partners with Exscientia to power the latter's platform for end-toend drug discovery and automation.
Business WireExscientia Launches AWS AI-powered Platform to Advance Drug Discovery
OXFORD, England, July 10, 2024--Exscientia plc (Nasdaq: EXAI) today announced it will be expanding its work with Amazon Web Services (AWS) to use the cloud provider’s artificial intelligence (AI) and machine learning (ML) services to power its platform for end-to-end drug discovery and automation.
© 2024 Yahoo. All rights reserved.